Yokohama, Japan

Hiromasa Takizawa


Average Co-Inventor Count = 11.8

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2001-2004

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hiromasa Takizawa: Innovator in Carbapenem Derivatives

Introduction

Hiromasa Takizawa is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel carbapenem derivatives. With a total of 3 patents to his name, Takizawa's work has the potential to impact the treatment of various bacterial infections.

Latest Patents

One of Takizawa's latest patents focuses on carbapenem derivatives. This invention discloses a novel carbapenem derivative that features a substituted imidazo[5,1-b]thiazole group at the 2-position on the carbapenem ring. These derivatives exhibit high antimicrobial activities against β-lactamase producing bacteria, MRSA, resistant strains, PRSP, enterococci, and influenza. Additionally, they demonstrate high stabilities to DHP-1. The patent provides a compound represented by a specific formula, or a pharmacologically acceptable salt or ester at the 3-position on the carbapenem ring.

Career Highlights

Hiromasa Takizawa is currently employed at Meiji Seika Kaisha, Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for resistant bacterial infections.

Collaborations

Throughout his career, Takizawa has collaborated with notable colleagues, including Yuko Kano and Toshiro Sasaki. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Hiromasa Takizawa is a distinguished inventor whose work in carbapenem derivatives is paving the way for new antimicrobial treatments. His contributions to the field are invaluable, and his ongoing research promises to enhance the effectiveness of combating resistant bacterial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…